Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial Meeting Abstract
| Authors: | Abou-Alfa, G. K.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Merle, P.; Park, J. W.; Blanc, J. F.; Bolondi, L.; Klumpen, H. J.; Chan, S. L.; Dadduzio, V.; Hessel, C.; Borgman-Hagey, A. E.; Schwab, G.; Kelley, R. K. |
| Abstract Title: | Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial |
| Meeting Title: | 2018 Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2018 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-02-01 |
| Language: | English |
| ACCESSION: | WOS:000436174100199 |
| DOI: | 10.1200/JCO.2018.36.4_suppl.207 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 207 -- Source: Wos |
